Information Provided By:
Fly News Breaks for October 8, 2018
LIFE
Oct 8, 2018 | 13:43 EDT
Piper Jaffray analyst Edward Tenthoff remained Overweight on aTyr Pharma, but lowered his price target on shares to $1.80 from $3, by "valuing ATYR-1923 in pulmonary sarcoidosis and rolling forward [the firm's] discount period to year end 2019." Tenthoff noted that aTyr plans to begin a Phase Ib/IIa placebo-controlled study for ATYR1923 to treat pulmonary sarcoidosis with preliminary data by year end 2019.
News For LIFE From the Last 2 Days
There are no results for your query LIFE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.